NASDAQ:NTRB Nutriband 4/29/2025 Earnings Report $5.32 0.00 (0.00%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$5.46 +0.15 (+2.73%) As of 04/25/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Nutriband EPS ResultsActual EPSN/AConsensus EPS -$0.12Beat/MissN/AOne Year Ago EPSN/ANutriband Revenue ResultsActual RevenueN/AExpected Revenue$0.71 millionBeat/MissN/AYoY Revenue GrowthN/ANutriband Announcement DetailsQuarterDate4/29/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Nutriband Earnings HeadlinesNutriband (NTRB) Expected to Announce Earnings on TuesdayApril 28 at 3:23 AM | americanbankingnews.comNutriband (NASDAQ:NTRB) Trading 1.4% Higher - Time to Buy?April 22, 2025 | americanbankingnews.comTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public. April 28, 2025 | Paradigm Press (Ad)Nutriband granted patent in Macao for its AVERA systemsApril 12, 2025 | markets.businessinsider.comNutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal TechnologyApril 11, 2025 | globenewswire.comNutriband (NASDAQ: NTRB) Signs Partnership Deal With Charlotte FC to Boost Brand VisibilityApril 5, 2025 | theglobeandmail.comSee More Nutriband Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nutriband? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nutriband and other key companies, straight to your email. Email Address About NutribandNutriband (NASDAQ:NTRB) develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.View Nutriband ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Upcoming Earnings AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025)Booking (4/29/2025)América Móvil (4/29/2025)Pfizer (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
